QIAGEN N.V. (NASDAQ:QGEN)
The Company is a provider of innovative technologies and products for preanalytical sample preparation and linked molecular assay solutions.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
There are currently 11100 QGEN shares in my "fund" with break-even of around 16.46 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
I have demoed their products on a regular basis in the my lab and most of the time I don't like them.
Recs
The growth potential of this industry is as unfathomable as those of Intel and Cisco. This is THE new growth industry. Look back 5-10 years ago; this stuff would ALL be science fiction. With this progression of discovery, optimization, and economies of scale, the costs will fall as new applications branch out with dizzying speed. This technology will be in the home in 25 years. What would we need it for? No way to predict.
Recs
Recent introduction of new tools; recent company acquisitions; eps good, relative price strength good; volume and price now pulling above 50 day moving average, looks to grow.
Recs
A sample and assay technology company with more than 500 consumable products and automated solutions-Netherlands based. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
Products are sold to a diverse customer base, including academic research centers, pharmaceutical and biotechnology companies, molecular diagnostics laboratories as well as to customers in applied testing markets such as forensics, animal or food testing, and pharmaceutical process control.
Recs
Biomed/Biotech should be one of the good segments in this economy.
Recs
genetic research will be as all consuming to our children's generation as communications have been to ours. humans are almost as compelled to look into themselves and communicate as they are to eat and mate. cisco anyone?
Recs
Better than GILD
Recs
buy the arms-dealers, not the army. see pitch for thermo-fisher.
Recs
Sure, it may drop near term... but the financials and the market timing seem right. Let's here about earnings on the 6th Aug.
Recs
Qiagen has a strong focus on R&D, and in light of increasing revenue and aquisitions has great potential at it's current price.
Recs
Qcube rocks...
Recs
exposure to RNAi, better valuation than Alnylam Pharmaceuticals Inc. (ALNY)
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 13 of 13